VJHemOnc is committed to improving our service to you

EBMT 2020 | TA-TMA: an increasingly identified complication post-transplant

VJHemOnc is committed to improving our service to you

Eleni Gavriilaki

Eleni Gavriilaki, MD, PhD, George Papanicolaou Hospital, Thessaloniki, Greece, discusses thrombotic microangiopathy (TMA), specifically highlighting transplant-associated TMA (TA-TMA). TA-TMA is an endothelial damage syndrome that’s increasingly found as a complication of autologous and allogeneic hematopoietic cell transplantation. Dr Gavriilaki goes on to discuss the therapeutic options for this complication such as the monoclonal antibody narsoplimab, which targets MASP-2. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter